ArticleNoro psikiyatri arsivi2026
Biomarkers of Endothelial Dysfunction in Cerebral Small Vessel Disease.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnetic Resonance Imaging in Cerebral Small Vessel Disease-Related Depression: From Visual Scoring to Artificial Intelligence.CNS neuroscience & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endothelial dysfunction (ED) plays a significant role in the development of cerebral small vessel disease (SVD). Analyzing biomarkers related to endothelial function, obtainable from peripheral blood, offers valuable insights for researchers. However, the link between biomarkers of ED and cerebral SVD remains controversial.Our primary aim was to investigate the relationship between the biomarkers of ED by analyzing intercellular adhesion molecule-1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1), asymmetric dimethylarginine (ADMA), interleukin-6 (IL-6), C-reactive protein (CRP), and specific clinical findings of cerebral small vessel disease (SVD), such as the presence of minor stroke or cognitive impairment. We also performed a correlation analysis between ED biomarkers and neuroimaging markers of cerebral SVD. Methods: Patients with cerebral SVD were grouped according to their symptoms. We compared the serum biomarkers of ED between patient groups. All biomarkers except CRP were studied using enzyme-linked immunosorbent assay. We also performed a correlation analysis between cerebral SVD biomarkers in neuroimaging and ED biomarkers. Results: We included 68 patients in this study. Patients with minor stroke or cognitive deficits had lower levels of PAI-1 than asymptomatic patients, and this finding was more evident in patients with cognitive deficits. Enlarged perivascular spaces (EPVSs) in the basal ganglia score positively but slightly correlated with serum ADMA levels. Conclusion: PAI-1 has a possible neuroprotective effect against the development of cognitive impairment in cerebral SVD. Biomarkers of ED differ according to the severity, and localization of the lesions. There was a specific relationship between ADMA and EPVSs in basal ganglia, -not EPVSs in the centrum semiovale- irrespective of vascular risk factors suggesting EPVSs in the centrum semiovale and basal ganglia may be the product of different pathological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.